上海联影医疗科技股份有限公司 关于 2024 年度会计师事务所的履职情况评估报告 （三）上市公司与前后任会计师事务所的沟通情况 根据《国有企业、上市公司选聘会计师事务所管理办法》等相关规范性文件 的规定，上海联影医疗科技股份有限公司（以下简称"公司"）对安永华明会计 师事务所（特殊普通合伙）（以下简称"安永华明"）在 2024 年度的审计工作的 履职情况进行了评估。经评估，公司认为安永华明在资质等方面合规有效，履职 保持独立性，勤勉尽责，公允表达意见。具体情况如下： 一、会计师事务所的基本情况 安永华明于 1992 年 09 月成立，2012 年 08 月完成本土化转制，从一家中外 合作的有限责任制事务所转制为特殊普通合伙制事务所。安永华明总部设在北京， 注册地址为北京市东城区东长安街 1 号东方广场安永大楼 17 层 01-12 室。 安永华明的首席合伙人为毛鞍宁。截至 2023 年 12 月 31 日，安永华明合伙 人人数为 245 人，注册会计师人数为 1,800 人，其中签署过证券服务业务审计报 告的注册会计师近 500 人。 二、前任会计师事务所的情况 （一）前任会计师事务所情况及上年度审计意见 公 ...

上海联影医疗科技股份有限公司 2024 年度 募集资金存放与实际使用情况专项报告 及鉴证报告 目录 上海联影医疗科技股份有限公司董事会： 我们接受委托，对后附的上海联影医疗科技股份有限公司 2024 年度募集资金存放 与实际使用情况的专项报告（"募集资金专项报告"）进行了鉴证。按照《上市公司监 管指引第 2 号——上市公司募集资金管理和使用的监管要求》、《上海证券交易所科创 板上市公司自律监管指引第 1 号——规范运作》及相关格式指南编制募集资金专项报告， 并保证其内容真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏是上海联影 医疗科技股份有限公司董事会的责任。我们的责任是在执行鉴证工作的基础上对募集资 金专项报告独立发表鉴证意见。 页码 | 一、募集资金存放与实际使用情况鉴证报告 | 1 - 2 | | --- | --- | | 二、上海联影医疗科技股份有限公司 2024 年度募集资金 | | | 存放与实际使用情况专项报告 | 3 - 9 | | 三、附表：2024 年度募集资金使用情况对照表 | 10 | 募集资金存放与实际使用情况鉴证报告 安永华明（2025）专字第70030227_B02号 ...

一、审计委员会基本情况 公司第二届董事会审计委员会由独立董事王少飞先生、盛雷鸣先生及非独立 董事沈思宇先生 3 名成员组成，其中独立董事占比为三分之二，并由具备会计专 业资格和经验的王少飞先生担任审计委员会主任委员。审计委员会的成员资格和 构成均符合有关法律法规的规定。 二、审计委员会会议召开情况 报告期内，审计委员会共召开 6 次会议，具体情况如下： | 会议名称 | | | 召开日期 | 会议内容 | | --- | --- | --- | --- | --- | | | | | | 审计委员会经过充分沟通讨论，一致审议通过《关于公司 | | 第二届董事会审计 | | | | 2023 年年度报告及摘要的议案》《关于公司 2023 年内部控制 | | 委员会 | 2024 | 年第一 | 2024.4.25 | 评价报告的议案》《关于公司 2023 年度财务决算报告的议案》 | | 次会议 | | | | 《关于续聘 2024 年度会计师事务所的议案》《关于公司 2024 | | | | | | 年第一季度报告的议案》 | | 第二届董事会审计 | | | | 审计委员会经过充分沟通讨论，一致审议通过《关 ...

Introduction to the Report Sustainable Development Management 2024 Environmental, Social and Governance Report Shanghai United Imaging Healthcare Co., Ltd. 1 Accessible and Inclusive Healthcare 03 14 20 27 38 56 Cutting-Edge Technology Lean Products and Quality Service Equality, Diversity and Common Growth Assuming Responsibilities and Joining in Public Benefit Activities Clean Production for Green Development 78 81 90 102 Compliant Operation for Steady Development Appendix 102 Index of Guidelines on Self-d ...

经核查独立董事 JIA HONG GAO、王少飞、盛雷鸣及其直系亲属和主要社会 关系人员的任职经历以及独立董事签署的相关自查文件，独立董事 JIA HONG GAO、 王少飞、盛雷鸣不存在《上市公司独立董事管理办法》第六条不得担任独立董事 的情形，在担任公司独立董事期间，独立董事已严格遵守中国证监会和上海证券 交易所的相关规定，确保有足够的时间和精力勤勉尽责地履行职责，作出独立判 断，不受公司主要股东、实际控制人或其他与公司存在利害关系的单位或个人的 影响。公司独立董事 JIA HONG GAO、王少飞、盛雷鸣符合《上市公司独立董事 管理办法》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》 中对独立董事独立性的相关要求。 上海联影医疗科技股份有限公司董事会 关于独立董事独立性情况的专项意见 根据《上市公司独立董事管理办法》《上海证券交易所科创板上市公司自律 监管指引第 1 号——规范运作》等要求，上海联影医疗科技股份有限公司（以下 简称"公司"）董事会，就公司截至本意见出具日在任的独立董事 JIA HONG GAO、 王少飞、盛雷鸣的独立性情况进行评估并出具如下专项意见： 上海联影医疗科技 ...

关于上海联影医疗科技股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 目 录 1、 专项审计报告 2、 附表 委托单位：上海联影医疗科技股份有限公司 审计单位：安永华明会计师事务所（特殊普通合伙） 联系电话：+86 10 5815 3000 Ernst & Young Hua Ming LLP Level 17, Ernst & Young Tower Orlental Plaza, I East Chang An Avenue Dongcheng District Beljing, China 100738 安永华朝会计师事务所(特殊营通合伙) 中国北京市东城区东长安街1号 东方广场安永大楼 17 层 邮政编码: 100738 Tel 电话:+86 10 5815 3000 Fax 传赢:+B6 10 8518 8298 ey.com 非经营性资金占用及其他关联资金往来情况的专项说明 上海联影医疗科技股份有限公司董事会: 我们审计了上海联影医疗科技股份有限公司的2024年度财务报表,包括2024年12 月31日的合并及公司资产负债表,2024年度的合并及公司利润表、股东权益变动表和 ...

Core Viewpoint - The China Securities Index for the medical industry has shown a decline in performance over various time frames, indicating potential challenges within the sector [2]. Group 1: Index Performance - The China Securities Index for the medical industry has decreased by 5.99% over the past month, 1.12% over the past three months, and 6.26% year-to-date [2]. - The index was established with a base date of December 31, 2021, set at 1000.0 points [2]. Group 2: Index Composition - The top ten weighted companies in the index include: - Mindray Medical (14.15%) - Aier Eye Hospital (9.35%) - United Imaging (8.03%) - Aimeike (4.1%) - Huatai Medical (3.87%) - New Industry (3.16%) - Shanghai Pharmaceuticals (3.11%) - Yuyue Medical (3.06%) - Yifeng Pharmacy (2.49%) - Meinian Onehealth (2.45%) [2]. - The index's holdings are primarily listed on the Shenzhen Stock Exchange (56.76%) and the Shanghai Stock Exchange (43.24%) [2]. Group 3: Sector Allocation - The sector allocation within the index is as follows: - Medical Devices: 34.77% - Medical Consumables: 22.92% - Pharmaceutical Commerce: 15.73% - Medical Services: 14.44% - In Vitro Diagnostics: 12.14% [2]. Group 4: Sample Adjustment - The index samples are adjusted biannually, with adjustments occurring on the next trading day following the second Friday of June and December [3]. - Weight factors are generally fixed until the next scheduled adjustment, with temporary adjustments made in response to significant events affecting sample companies [3].

Investment Rating - The report maintains an "Accumulate" rating for the pharmaceutical and biotechnology sector [4]. Core Viewpoints - The domestic weight loss drug market is entering commercialization, emphasizing the importance of sales capabilities for companies [1][19]. - The competition in the global weight loss drug market is intensifying, particularly between Novo Nordisk and Eli Lilly, where marketing strategies play a crucial role in sales performance [19][23]. - Companies with advanced R&D progress and strong sales execution will hold competitive advantages in the commercialization phase of weight loss drugs [1][19]. Summary by Sections Market Review - The pharmaceutical and biotechnology index rose by 1.16%, outperforming the CSI 300 index by 0.77 percentage points but underperforming the ChiNext index by 1.08 percentage points, ranking 15th among 31 sub-industries [1][15]. - The Hong Kong Hang Seng Healthcare Index increased by 8.44%, outperforming the Hang Seng Index by 6.12 percentage points [1][15]. Company Updates - Recent clinical application updates include Baiyi Shenzhou's injection BGB-B2033 and Nuo Cheng Jian Hua's injection ICP-B794, both newly undertaken [27]. - Ongoing clinical trials include Bo Rui Pharmaceutical's BGM0504 and Hua Dong Pharmaceutical's HDM1002, currently in Phase III [27]. Investment Strategy - The report suggests a structural selection of investment opportunities based on payment willingness and ability, focusing on three payment channels: in-hospital payments, out-of-pocket payments, and overseas payments [2]. - Key recommended companies include Heng Rui Pharmaceutical, Mai Rui Medical, and United Imaging Healthcare [2]. Company Profit Forecasts and Valuation - Heng Rui Pharmaceutical is rated "Accumulate" with a projected EPS of 0.99 yuan for 2024 and a PE ratio of 51 [3]. - Mai Rui Medical is rated "Buy" with a projected EPS of 11.47 yuan for 2024 and a PE ratio of 19 [3]. - United Imaging Healthcare is also rated "Buy" with a projected EPS of 2.88 yuan for 2024 and a PE ratio of 44 [3].

Core Insights - The healthcare sector in Hong Kong is experiencing mixed performance, with the 中证港股通医药卫生综合指数 down by 2.09% as of April 28, 2025, while the 港股医药ETF has shown a weekly increase of 6.99% as of April 25, 2025 [1][4][7] Group 1: Market Performance - The 中证港股通医药卫生综合指数 has decreased by 2.09% as of April 28, 2025, with notable gainers including 心泰医疗 up 6.75% and 国药控股 up 3.79% [1] - The 港股医药ETF has a latest price of 0.7 yuan, reflecting a 2.09% decline, but has seen a 6.99% increase over the past week [1] - The 中证医药及医疗器械创新指数 has decreased by 0.52% as of April 28, 2025, with 百利天恒 leading gains at 4.77% [4] Group 2: Liquidity and Trading Activity - The 港股医药ETF had a turnover rate of 16.09% with a trading volume of 42.87 million yuan, indicating active market participation [1] - The 医疗创新ETF had a turnover rate of 1.2% and a trading volume of 19.80 million yuan [4] - The 港股医药ETF has seen a significant increase in scale, growing by 52.31 million yuan over the past two weeks [1] Group 3: Fund Flows and Investment Trends - The 港股医药ETF has attracted a total of 37.93 million yuan in net inflows over the last five trading days [1] - The 医疗创新ETF has recorded a net inflow of 13.66 million yuan, with a total of 14.22 million yuan over the last ten trading days [4] - Leverage funds are increasingly being utilized, with the 医疗创新ETF showing a financing buy amount of 4.79 million yuan [4] Group 4: Company Developments - Several innovative pharmaceutical companies in Shanghai have reported profitability driven by sales of innovative products, highlighting their full-chain innovation capabilities [7] - The trend of going global is common among these innovative drug companies, with products like 呋喹替尼 receiving approval in the U.S. market [7] - The integration of "R&D-production-sales" is accelerating, with leading pharmaceutical companies transitioning from biotech to biopharmaceutical firms [8]

Core Insights - The Shanghai Stock Exchange Science and Technology Innovation Board Composite Index (000680) has shown a slight increase of 0.08% as of April 28, 2025, with notable gains in constituent stocks such as Deep Science and Technology (688328) up by 16.51% and Link Measurement Technology (688113) up by 8.90% [3] Market Performance - The Huaxia Science and Technology Innovation Index ETF (589000) experienced a trading volume of 61.31 million yuan with a turnover rate of 1.83% [3] - The ETF's average daily trading volume over the past week reached 214 million yuan, ranking it first among comparable funds [3] - The latest scale of the Huaxia ETF reached 3.372 billion yuan, marking a new high since its inception and placing it in the top 1/12 of comparable funds [3] - The ETF's share count has also reached 3.640 billion shares, another record high since inception, maintaining its position in the top 1/12 of comparable funds [3] Fund Inflows - The Huaxia ETF has seen continuous net inflows over the past 12 days, with a peak single-day net inflow of 1.361 billion yuan, totaling 2.579 billion yuan in net inflows [3] Policy Insights - The Central Political Bureau meeting on April 25, 2025, discussed the current economic situation and proposed new structural monetary policy tools to support technological innovation, expand consumption, and stabilize foreign trade [3] - According to Zhongyin International, the market may experience a temporary slowdown in upward momentum following the meeting, but the downside risks remain manageable [3] - The current low valuation levels and favorable Q1 fundamental data are expected to support the market against significant downward risks, although future trends will depend on clearer policy releases or fundamental recovery expectations [3] Investment Strategy - The current investment focus is on domestic demand and self-sufficiency, which are identified as the two main lines of allocation [3] - Once the uncertainty surrounding tariffs stabilizes, profitability factors are expected to regain dominance in the market, potentially leading to a return to growth styles, with the AI industry chain likely becoming a focal point again [3]